In the liver, the activation of AMPK blocks the synthesis of fatty acids, TG, cholesterol, and proteins while activating oxidative processes13,19,20, and it has been shown that obese, diabetic, or non-alcoholic fatty liver disease (NAFLD) individuals have decreased hepatic AMPK11,12. Here, PRKAA2 is linked to metabolic dysfunction-associated steatotic liver disease.